Navigation Links
NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors
Date:10/21/2009

SOUTH SAN FRANCISCO, Calif., Oct. 21 /PRNewswire/ -- NGM Biopharmaceuticals, Inc. (NGM), a private company dedicated to the discovery and development of novel biotherapeutics for the treatment of Type 2 diabetes and other metabolic diseases, today announced that Arthur D. Levinson, Ph.D., the Chairman of Genentech's Board of Directors, has been appointed to NGM's Board of Directors. Under Dr. Levinson's leadership as Chairman and Chief Executive Officer from 1995 to 2009, Genentech became a leading global therapeutics company that was widely recognized as the most innovative biotechnology company in the industry.

Founded in 2008, NGM has created a proprietary discovery platform and pipeline based on biological insights into the relationship between bariatric gastric bypass surgery and post-surgical resolution of Type 2 diabetes and other metabolic disorders. Dr. Levinson will join other distinguished advisors in guiding the Company's research, development and business strategies.

"NGM has the attributes and values that I believe are fundamental to building an innovative and sustainable biotechnology company," said Dr. Levinson. "The company's creative approach to scientific research should provide new insights into disease processes, and support the discovery of differentiated, clinically important medicines."

"Art's accomplishments and leadership during his thirty years at Genentech are legendary," said David V. Goeddel, Ph.D., NGM's Chairman and Chief Executive Officer. "His scientific and business acumen will be invaluable in shaping NGM's continued progress."

Dr. Levinson is currently the chairman of Genentech's Board of Directors, an advisor to Genentech's Research and Early Development center and a member of Roche's Scientific Resource Board. In addition, he will be nominated to the Board of Directors of Roche Holding Ltd. in March 2010. Among his significant commitments are his memberships on the Board of Directors of the Broad Institute of the Massachusetts Institute of Technology and the Board of Scientific Consultants of Memorial Sloan-Kettering Cancer Center.

Dr. Levinson is the recipient of numerous awards and honors, including the Irvington Institute's 1999 Corporate Leadership Award in Science, the National Breast Cancer Coalition's Corporate Leadership Award, Institutional Investor's Best Biotech CEO award, Princeton University's James Madison Medal for a distinguished career in scientific research and in biotechnology, Barron's designation as one of "The World's Most Respected CEOs" and the Best Practice Institute's "25 Top CEOs." Dr. Levinson also serves on the board of directors of Apple Inc.

About NGM Biopharmaceuticals

NGM Biopharmaceuticals, Inc. is a privately held drug discovery and development company dedicated to developing transformational medicines that significantly improve human health. NGM has devised a novel discovery platform, relying on human clinical and genetic observations, to identify and validate targets that impact the underlying etiology of disease. The Company's strategy is to focus on mining the complex biological interactions within the neuroendocrine gastrointestinal environment to elucidate the roles of previously unidentified or unexplored hormones, receptors and other metabolic factors that are involved in the systemic regulation of glucose homeostasis and that play causative roles in diseases.

NGM is generating a rich pipeline of new targets that the Company is using to develop novel treatments for metabolic diseases, such as obesity, muscle wasting and cardiovascular disease in addition to diabetes. Founded in 2008, NGM has world-class scientists and an accomplished executive team with broad experience in building and managing biotechnology companies. NGM is headquartered in South San Francisco, California. For more information, please visit the Company's website at http://www.ngmbio.com.

SOURCE NGM Biopharmaceuticals, Inc.


'/>"/>
SOURCE NGM Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
2. Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b Trial
3. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
4. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
5. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
6. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
7. XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma
8. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
9. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
10. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
11. XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/8/2017)... Fla. , June 8, 2017  Less than ... that hit more than 200,000 companies, including hospital networks, ... being heralded as one of the largest online extortion ... in the healthcare market, it is imperative that providers ... protect their data from this — and many other ...
(Date:6/7/2017)... June 7, 2017 Endo International plc (NASDAQ: ... 2017, the Hon. Joseph R. Goodwin , U.S. ... West Virginia , entered a case management ... Repair System Products Liability Litigation (the "MDL") that includes ... to provide expert disclosures on specific causation within one ...
(Date:6/5/2017)... 2017 The Cincinnati location ... Inc. (NYSE: DPLO), has been awarded a Top Workplaces ... Results are based on an employee survey administered by ... workplace improvement. The survey measures several aspects of workplace culture, ... ...
Breaking Medicine Technology:
(Date:6/26/2017)... ... 26, 2017 , ... New patients with missing teeth in Fitchburg, ... a referral. Dr. Cotey is a trusted dentist who has placed many dental implants ... Patients with missing teeth in Fitchburg, WI, are encouraged to find out if they ...
(Date:6/25/2017)... ... June 24, 2017 , ... Create a feel-good lyric music video in Final Cut Pro X ... the timeline and write in the lyrics to any song. ProLyric flies in the text ... of the text can be added modularly for optimal control. ProLyric makes editing any music ...
(Date:6/25/2017)... ... 25, 2017 , ... An increase in wetter weather in the Northern California ... with that; a humdinger of an allergy season. A relief from drought conditions is ... misery-causing grass and weed pollen. , “Our patients have been reporting the typical ...
(Date:6/25/2017)... ... ... With a heatwave currently bearing down on Northern California pushing temperatures to the maximum, many ... is easy with laser hair removal. , The process of summer waxing and constantly ... all you want to do is get out, dive in and cool off. There is ...
(Date:6/24/2017)... , ... June 24, 2017 , ... ... offering genetic testing for medications in select Florida and Texas doctors' offices and ... , This new application of genetic testing recognizes the role genes play in ...
Breaking Medicine News(10 mins):